Discovery and Administration Optimization of Novel Selective CDK9 Inhibitor, 1-7a-B1, for Improved Pharmacokinetics and Antitumor Efficacy In Vivo.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.5c00472
Abstract: Cyclin-dependent kinase 9 (CDK9) is a member of the transcriptional CDK subfamily. In this work, a de novo design strategy was used to obtain a series of novel CDK9 inhibitors. A novel selective CDK9 inhibitor… read more here.
Keywords: cdk9; cdk9 inhibitor; pharmacokinetics antitumor; improved pharmacokinetics ... See more keywords
A Phase 1 Study of the Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-198718
Abstract: Background: Venetoclax in combination with hypomethylating agents (HMA) or low dose cytarabine is the standard of care for patients (pts) with newly diagnosed AML ineligible for intensive chemotherapy. However, responses are transient, and loss of… read more here.
Keywords: cdk9 inhibitor; combination; oral cdk9; study ... See more keywords